<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of hereditary hemochromatosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of hereditary hemochromatosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of hereditary hemochromatosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pradyumna Phatak, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Domenico Girelli, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert T Means, Jr, MD, MACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hereditary hemochromatosis (HH) is most commonly due to homozygosity for the C282Y variant in the <em>HFE</em> gene. HH is a disorder in which increased intestinal iron absorption can lead to total-body iron overload.</p><p>The<em> HFE</em> C282Y variant is quite common; however, not all individuals with this variant develop iron overload. Evaluation and diagnosis of HH requires integration of genetic information with other markers of tissue iron deposition. </p><p>This topic reviews the pathophysiology, epidemiology, clinical manifestations, and diagnosis of HH. </p><p>Separate topics discuss the genetics of HH, regulation of iron balance, population screening for HH, and management:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetics of HH, including disease variants in genes other than <em>HFE</em> – (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interpretation of <em>HFE</em> genetic testing – (See  <a class="medical medical_review" href="/d/html/123113.html" rel="external">"Gene test interpretation: <i>HFE</i> (hereditary hemochromatosis gene)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of suspected iron overload from any cause – (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for HH in the general population – (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Role of population screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of HH, including individuals with biallelic <em>HFE</em> variants who do not have iron overload – (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="headingAnchor" id="H266432195"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The term "hemochromatosis" is often used to indicate iron overload generally, but it is best applied to the distinct genetic disorder due to pathogenic mutations in genes regulating hepcidin, thereby leading to hyperabsorption of iron and its progressive accumulation in the body [<a href="#rid1">1</a>].</p><p>The disease is genetically heterogeneous since mutations in at least five genes (<em>HFE</em>, <em>HJV</em>, <em>HAMP</em>, <em>TFR2</em>, and <em>SLC40A1C</em>) can contribute  (<a class="graphic graphic_table graphicRef56329" href="/d/graphic/56329.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>.) </p><p>Nonetheless, most cases of hereditary hemochromatosis (HH, also called genetic hemochromatosis) occur in White European people and are caused by homozygosity for the C282Y variant in the <em>HFE</em> gene (<em>HFE</em> C282Y/C282Y). This is often referred to as "classical hemochromatosis" or "<em>HFE</em>-hemochromatosis." Significant iron overload develops in &lt;20 percent of C282Y homozygotes. (See <a class="local">'Epidemiology'</a> below.)</p><p>The terminology for individuals who are homozygous for the <em>HFE</em> C282Y variant and do not have iron overload is not well established; there are not clear guidelines in the genetics community. Such individuals did not come to clinical attention in the era before genetic testing. These individuals may be referred to as "non-expressing homozygotes," or "C282Y/C282Y genotype without iron overload," or in other ways that denote the <em>HFE</em> genotype and the non-iron-overload phenotype.</p><p class="headingAnchor" id="H811219481"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span><em>HFE</em> gene C282Y homozygosity (or, rarely, pathogenic variants in another gene that regulates iron uptake) is necessary but not sufficient for the development of hemochromatosis (clinical iron overload). It generally takes several decades (until the fifth decade of life or later) of excess iron absorption without concomitant blood loss for clinically significant tissue iron deposition to occur. An exception may be represented by homozygous pathogenic variants in the <em>HJV</em> or in the <em>HAMP</em> genes, which can result in juvenile hemochromatosis, with clinical onset in the second to third decade of life. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Non-HFE hemochromatosis'</a>.)</p><p class="headingAnchor" id="H412051935"><span class="h2"><i>HFE</i> gene variants</span><span class="headingEndMark"> — </span>HH is an autosomal recessive disorder with low penetrance. This means that homozygosity for the C282Y variant is usually required for clinical disease, but many individuals who are homozygous for C282Y will not be affected. (See <a class="local">'Epidemiology'</a> below.)</p><p>Pathogenic variants in the <em>HFE</em> gene are seen in the majority of individuals with HH. Two common variants are seen [<a href="#rid2">2-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>C282Y</strong> – Guanine to adenine change at nucleotide 845 in the <em>HFE</em> gene that causes substitution of cysteine for tyrosine at amino acid 282</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>H63D</strong> – Cytosine to guanine change at nucleotide 187 in the <em>HFE</em> gene that causes substitution of histidine to aspartic acid at amino acid 63</p><p></p><p>Homozygosity for C282Y is more commonly associated with clinical disease, accounting for &gt;90 percent of HH cases in White European populations. Compound heterozygosity (C282Y/H63D), homozygous <em>HFE</em> gene deletion, and heterozygosity for C282Y have also been reported in patients with iron overload, but generally individuals who carry the H63D variant have other risk factors for iron overload such as liver disease. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'HFE variants in hereditary hemochromatosis'</a>.)</p><p class="headingAnchor" id="H2718296223"><span class="h2">Genotype-phenotype correlations</span><span class="headingEndMark"> — </span>The likelihood of iron overload according to <em>HFE </em>genotype has been estimated from various population studies such as the Hemochromatosis and Iron Overload Screening (HEIRS) study, which evaluated over 100,000 individuals in primary care practices in the United States and Canada [<a href="#rid5">5-7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homozygous C282Y/C282Y</strong> – ≥10 percent, depending on the population tested and the criteria used; continues to decrease as more individuals are diagnosed before they develop iron overload. (See <a class="local">'Epidemiology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compound heterozygous C282Y/H63D</strong> – Significantly less common than with C282Y/C282Y, although the absolute risk is challenging to characterize; one study found hepatic fibrosis in 13 of 51 C282Y/H63D compound heterozygotes (25 percent) [<a href="#rid8">8</a>]. However, all of the individuals with ferritin levels &gt;1000 ng/mL (&gt;1000 mcg/L) had at least one other comorbid factor that could have contributed to the increase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homozygous H63D/H63D</strong> – Significantly less common than with C282Y/C282Y, although the absolute risk is challenging to characterize; one study found iron overload in 4 of 60 H63D homozygotes (7 percent) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heterozygous (C282Y/wild type or H63D/wild type)</strong> – Similar to the general population.</p><p></p><p>The likelihood of iron overload with a particular genotype appears to be higher in first-degree relatives of those with iron overload, suggesting that other genetic or environmental modifiers may be contributing to the iron-overload phenotype [<a href="#rid6">6</a>]. </p><p>For those with non-C282Y/C282Y <em>HFE</em> genotypes who develop iron overload, the degree is generally less severe [<a href="#rid7">7</a>]. </p><p>Disease variants in genes that encode other iron regulatory proteins have been described less commonly; these include genes for hemojuvelin (<em>HJV</em>), hepcidin (<em>HAMP</em>), transferrin receptor 2 (<em>TFR2</em>), and ferroportin (<em>SLC40A1C</em>)  (<a class="graphic graphic_table graphicRef56329" href="/d/graphic/56329.html" rel="external">table 1</a>). Details are discussed separately. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>.) </p><p>Heterozygosity for the <em>HFE</em> C282Y variant is so common in some populations that the carrier state likely was neutral or beneficial at some point in human evolution and thus may have undergone selection pressure. The point mutation arose around 4000 BC in Celtic populations in central Europe and spread west and north [<a href="#rid10">10</a>]. It has been proposed to have been selected because increased iron absorption was desirable, especially in females of childbearing age who were consuming a grain-based diet [<a href="#rid11">11,12</a>]. Other possible beneficial effects of heterozygosity have been suggested related to immune function, exercise tolerance, and reduced incidence of certain neurodegenerative disorders, although these remain hypothetical [<a href="#rid11">11,13</a>].</p><p class="headingAnchor" id="H3930977029"><span class="h2">Iron overload</span><span class="headingEndMark"> — </span>Not all individuals who are homozygous for the <em>HFE </em>C282Y variant develop iron overload and clinical HH. Other genetic and/or environmental factors, as well as other medical conditions, dietary iron intake, blood transfusions, and blood loss (from physiologic bleeding such as menstruation or blood donations, or pathologic bleeding) likely play a role in the manifestation of clinically significant body iron burden. </p><p>For those who are affected, classic HH generally does not become clinically manifest until later in adulthood when significant total-body iron accumulation has occurred. (See <a class="local">'Time course'</a> below.)</p><p>The retained iron is primarily deposited in parenchymal cells (initially in periportal hepatocytes), with reticuloendothelial cell accumulation (eg, in hepatic Kupffer cells) occurring very late in the disease [<a href="#rid14">14</a>]. This is thought to be because low hepcidin levels also interfere with storage by reticuloendothelial cells, similar to its effect on intestinal epithelial cells [<a href="#rid5">5</a>]. It contrasts with transfusional iron overload, in which iron deposition occurs first in the reticuloendothelial cells and then in parenchymal cells. Typically, this accumulation follows a progression from clinically inapparent to clinically apparent disease:</p><p class="bulletIndent1"><span class="glyph">●</span><em>HFE</em> C282Y leads to inappropriately low levels of hepcidin by interfering with its physiological upregulation as iron stores increase [<a href="#rid1">1,15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low hepcidin levels result in increased intestinal iron absorption (both heme and non-heme iron).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Over years to decades, the amount of absorbed iron reaches many grams.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron accumulates in the liver, heart, pituitary gland, pancreas, and other tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organ and tissue damage occurs by an incompletely understood mechanism that may include oxygen free radicals.</p><p></p><p>In individuals without HH, approximately 1 mg per day of iron is absorbed from a typical Western diet. In contrast, in individuals with HH, iron absorption is as high as 2 to 4 mg per day. To some extent, iron absorption is mitigated by iron loss, more so in premenopausal females. Iron loss occurs by a number of mechanisms including normal losses in sweat and shedding of cells from the skin and the gastrointestinal tract; this accounts for approximately 1 mg of iron lost per day. Other than these obligate losses, there is no physiologic mechanism for excretion of excess iron once it has been absorbed. In premenopausal females, an average of approximately 0.5 to 1 additional mg is lost per day from menses and approximately 1 gram from a term pregnancy (more with lactation). (See  <a class="medical medical_review" href="/d/html/115637.html" rel="external">"Anemia in pregnancy", section on 'Iron deficiency'</a>.)</p><p>Symptoms can be pleiotropic, but they are all related to end-organ damage caused by iron deposition.</p><p>The physiology of iron balance and the roles of other regulators are described in more detail separately. (See  <a class="medical medical_review" href="/d/html/7105.html" rel="external">"Regulation of iron balance"</a> and  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>.)</p><p class="headingAnchor" id="H2845883625"><span class="h2">Time course</span><span class="headingEndMark"> — </span>Patients generally become symptomatic when organ iron deposition has been ongoing for decades and total body accumulation is as high as 20 grams. As a result, the clinical manifestations of HH typically occur after age 40 in males and later in females.</p><p class="bulletIndent1"><span class="glyph">●</span>A male who is homozygous for <em>HFE </em>C282Y will absorb 2 to 4 mg of iron per day, rather than the 1 mg/day needed to balance iron losses. If he absorbs 4 mg/day of iron, this leads to the retention of 3 mg of iron more per day than is needed to maintain iron balance and will result in a net iron accumulation of approximately 1 gram/year. If there are no other major needs for iron following the adolescent growth spurt, it will not be until age 40 or 50 that total iron accumulation will reach more than 20 grams of iron. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A female homozygous for <em>HFE</em> C282Y who absorbs 4 mg/day of iron and has regular menstrual blood loss will only retain 2 mg of iron per day more than needed for iron balance, which will result in a net iron accumulation of approximately 700 mg/year. It will take 10 years longer (to age 50 or 60) to reach a total iron accumulation of 20 grams of iron. </p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>HH was previously thought to be a rare disorder, since the diagnosis was only made in individuals who presented with severe iron overload; it is now appreciated as one of the most common genetic disorders in individuals with European ancestry [<a href="#rid17">17</a>]. It is less common in individuals with ancestry from other regions of the world (Africa, Asia, South America) [<a href="#rid1">1,17</a>].</p><p>Studies from the 1980s and 1990s suggested that an abnormality of increased iron absorption (consistent with a carrier state) was extremely common in Europe, approaching a gene frequency of 7 percent and a disease prevalence of 0.2 to 0.7 percent [<a href="#rid18">18-21</a>].</p><p>Once the <em>HFE</em> gene was identified in 1996, further estimates from population screening have found it to be present in 6.4 percent of White Americans and 4 to 5 percent of White Europeans; it is extremely rare in individuals in East Asia (&lt;0.1 percent) [<a href="#rid2">2,6,22</a>]. In East Asia, hemochromatosis is mainly due to pathogenic variants in genes other than <em>HFE</em>, such as <em>HJV</em>, <em>HAMP</em>, <em>TFR2</em>, and rare gain of function mutations in <em>SLC40A1</em>; these are collectively referred to as "non-HFE hemochromatosis" [<a href="#rid1">1,23</a>]. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Non-HFE hemochromatosis'</a>.)</p><p>Homozygosity for the C282Y variant is seen in approximately 1 in 150 to 1 in 300 individuals in various White populations [<a href="#rid24">24</a>]. The implications for population screening are discussed separately. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Role of population screening'</a>.)</p><p>HH is a low-penetrance disorder (see <a class="local">'Genotype-phenotype correlations'</a> above); males are more commonly affected with severe iron overload than females. One analysis of the published data from a number of sources determined that the likelihood of severe liver disease in untreated males who were homozygous for <em>HFE </em>C282Y was approximately 1 in 10 [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4081000495"><span class="h2">Typical presentations</span><span class="headingEndMark"> — </span>Prior to the identification of the <em>HFE</em> gene, patients with HH often presented with symptoms attributable to high levels of tissue iron deposition. Increased awareness of the disorder, routine availability of iron studies, and identification of the <em>HFE</em> gene have converted the typical presentation of HH from an end-stage disease of severe iron overload to a laboratory diagnosis often made in asymptomatic individuals. </p><p>The severity of presentation depends on the extent of iron overload. Thus, individuals with HH in the modern era are more likely to present with the finding of high ferritin levels and/or biallelic C282Y variants in the <em>HFE</em> gene than in the past. (See <a class="local">'Epidemiology'</a> above.) </p><p>Presentations associated with significant iron overload are rare in younger individuals. Males typically present at age 40 or older, and females generally present after menopause due to slower iron accumulation in the premenopausal years [<a href="#rid17">17</a>]. (See <a class="local">'Time course'</a> above.)</p><p>However, organ toxicity continues to be seen, and affected individuals continue to present with symptoms of HH. For the most part, these symptoms reflect the consequences of iron deposition in one or more organs, although symptoms are often nonspecific (fatigue, lethargy, apathy). (See <a class="local">'General/systemic symptoms'</a> below.) </p><p>The following observations illustrate the variation among common presentations:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Hemochromatosis and Iron Overload Screening (HEIRS) study, which screened approximately 100,000 individuals in the United States and Canada for HH, only 72 of 299 (24 percent) had been diagnosed with iron overload, suggesting that the other 76 percent were asymptomatic at the time of testing [<a href="#rid6">6,26</a>]. Participants were asked to identify any HH-associated symptoms before their <em>HFE</em> genotype results were available, and commonly reported symptoms included chronic fatigue, skin hyperpigmentation, swelling of the second and third metacarpal phalangeal joints, and generalized joint stiffness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a French survey study involving 374 individuals with HH, the mean age at diagnosis was 49 years [<a href="#rid27">27</a>]. The initial finding that led to the diagnosis was a first-degree relative's diagnosis in 29 percent, an incidental finding of high ferritin in 26 percent, and clinical symptoms in 45 percent. The most common symptoms were fatigue, joint pain, or symptoms of liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 214 first-degree relatives (mostly siblings) of individuals with HH who were themselves homozygous for the C282Y variant but had not sought medical attention for symptoms of iron overload, evidence of iron overload was found in 85 percent of males and 68 percent of females [<a href="#rid28">28</a>]. Of males over 40 years of age, approximately one-half had at least one disease-related condition such as liver disease or arthropathy; of women over 50 years of age, approximately one in six had at least one disease-related condition. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 451,243 individuals of European ancestry in the UK Biobank, 2890 (0.6 percent) were homozygous for the C282Y variant [<a href="#rid29">29</a>]. Of these individuals, with an age range 40 to 70 years, HH had been diagnosed in 22 percent of males and 10 percent of females. Compared with individuals lacking the C282Y variant, individuals who were homozygous for C282Y had increased likelihood of several associated complications. As examples, males had an increased risk of developing significant liver disease (odds ratio [OR] 4.3, 95% CI 2.97-6.18) and females had an increased likelihood of developing arthritis (OR 1.33, 95% CI 1.15-1.93).</p><p></p><p>In contrast, individuals diagnosed in an earlier era, before <em>HFE </em>testing and routine iron studies, often had multiple symptoms and laboratory abnormalities [<a href="#rid30">30</a>]. In a report that evaluated 251 patients diagnosed with HH from 1959 to 1992, the following were noted at presentation [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function abnormalities – 75 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Weakness and lethargy – 74 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Skin hyperpigmentation – 70 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus – 48 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Arthralgia – 44 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Impotence in males – 45 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiographic abnormalities – 31 percent</p><p></p><p class="headingAnchor" id="H2186559362"><span class="h2">General/systemic symptoms</span><span class="headingEndMark"> — </span>Fatigue (in the absence of anemia), pain, and nonspecific symptoms are commonly reported in individuals with HH.</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of &gt;200,000 individuals 60 to 70 years of age who participated in a United Kingdom Biobank survey, the 1312 <em>HFE</em> C282Y homozygotes were more likely to have chronic pain, sarcopenia, and frailty (odds ratios [OR] in the range of 1.2 to 2.4) [<a href="#rid32">32</a>]. Generalized pain from arthritis can affect quality of life. (See <a class="local">'Arthropathy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 395 individuals referred to a hepatology center with HH, 170 (43 percent) met diagnostic criteria for fibromyalgia syndrome (FMS) [<a href="#rid33">33</a>]. Many had widespread pain, depression, and/or joint stiffness. One-third of those with FMS had some degree of functional impairment.</p><p></p><p>The mechanisms of fatigue and generalized pain are not well understood, and many of our patients do not report these symptoms. Some of the symptoms are so vague and nonspecific (weakness, apathy) that they may be omitted from the patient's medical record [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H4257910518"><span class="h2">Manifestations of organ iron overload</span><span class="headingEndMark"> — </span>Iron can deposit in any organ. Although the distribution of iron can differ among patients, deposition in the liver generally occurs first because blood containing iron absorbed from the gastrointestinal tract passes through the liver first before other organs. Thus, it is unusual to see significant cardiac or endocrine iron overload in the absence of significant liver iron deposition.</p><p>The clinical manifestations of iron overload can be influenced by the amount of tissue iron and the presence of other conditions that lead to organ dysfunction. Thus, a 60-year-old male who presents with clinical findings is likely to have much greater and more extensive tissue iron overload than a younger person or a female having regular menstrual periods or pregnancies; an individual with concomitant excess alcohol use or hepatitis C virus (HCV) infection is likely to develop liver injury at a younger age than one without these comorbidities.</p><p class="headingAnchor" id="H3125877457"><span class="h3">Hepatic iron overload</span><span class="headingEndMark"> — </span>The liver is the principal site of normal iron storage and is a major site of iron deposition in HH. Hepatic iron overload can lead to:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly</p><p class="bulletIndent1"><span class="glyph">●</span>Increased hepatic transaminases</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic fibrosis, which may progress to cirrhosis</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatocellular cancer (HCC) </p><p></p><p>In the HEIRS study (see <a class="local">'Genotype-phenotype correlations'</a> above), the OR for liver disease in male C282Y/C282Y homozygotes was 3.3 (95% CI 1.5-7.2); in male compound C282Y/H63D heterozygotes, the likelihood of liver disease was increased to a lesser degree (OR 1.7, 95% CI 1.0-2.7) [<a href="#rid6">6</a>]. The reversibility of hepatic injury depends on how early in the disease course the treatment is started. However, as discussed separately, even in individuals with cirrhosis and esophageal varices, iron removal can lead to regression of fibrosis [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p>In a meta-analysis of observational studies from 2016 that included nearly 6000 cases of HH and nearly 15,000 controls, C282Y homozygotes had an increased risk of nonalcoholic fatty liver disease (NAFLD) and HCC but not cirrhosis [<a href="#rid35">35</a>]. Iron deposition in the hepatocytes of individuals with HH is not inflammatory. Thus, hepatic fibrosis can sometimes occur without an increase in serum transaminases. </p><p>On the other hand, many individuals with HH also have an accompanying inflammatory liver condition (hepatic steatosis, alcoholic liver disease, hepatitis B virus [HBV] or HCV), with higher median transaminase levels than those with HH unaccompanied by one of these disorders. Liver injury may be more pronounced in individuals with other medical conditions that contribute to liver injury such as excessive alcohol use, NAFLD, or HBV or HCV infection. In one retrospective study of 200 patients with documented HH, 43 percent had at least one additional cause of chronic liver disease [<a href="#rid26">26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohol</strong> – Excess alcohol intake is a major risk factor for the development of liver disease in patients with HH, and iron overload potentiates the development of alcoholic liver disease [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral hepatitis</strong> – Case reports and small series have suggested that HH-induced iron overload also appears to potentiate hepatic fibrosis in individuals with HCV infection [<a href="#rid38">38,39</a>].</p><p></p><p>The above observations are explained by the fact that both alcohol and HCV infection suppress hepcidin production, thus exacerbating the underlying genetic disorder [<a href="#rid15">15,40</a>]. They also indicate that the diagnosis of HH can be made even in individuals with normal transaminase levels and emphasize the importance of investigating the possibility that another condition such as excess alcohol use may be contributing to liver disease. (See <a class="local">'Diagnostic criteria'</a> below and <a class="local">'Post-diagnostic testing'</a> below.)</p><p class="headingAnchor" id="H245076412"><span class="h3">Cardiac iron overload</span><span class="headingEndMark"> — </span>The heart is another major site of iron deposition in HH [<a href="#rid41">41,42</a>]. Cardiac iron overload can lead to the following complications [<a href="#rid17">17,43-46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dilated cardiomyopathy, diastolic dysfunction, and heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Conduction disturbances, sinus node dysfunction (previously called sick sinus syndrome), and arrhythmias; rarely, sudden cardiac death</p><p></p><p>In some individuals, heart disease may be the first manifestation of HH, although these individuals are likely to have significant liver iron deposition as well. Isolated heart disease does not preclude the diagnosis of HH. Cardiac involvement can be usefully assessed by magnetic resonance imaging (MRI) [<a href="#rid47">47</a>]; some individuals with unexplained cardiomyopathy may also undergo endomyocardial biopsy. (See <a class="local">'MRI'</a> below and  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Other tests for selected individuals'</a>.)</p><p>As with hepatic iron overload, cardiac abnormalities may be reversible in some patients [<a href="#rid44">44-46</a>]. </p><p>It has been proposed that HH or other forms of iron overload might reduce the incidence of atherosclerotic heart disease, based on results in animal models and autopsy studies of individuals with HH [<a href="#rid48">48,49</a>]. This association remains controversial, with other studies showing an increased risk or no relationship between iron stores, HH, and ischemic heart disease [<a href="#rid50">50-57</a>].</p><p class="headingAnchor" id="H411890883"><span class="h3">Endocrine organs</span><span class="headingEndMark"> — </span>Iron can deposit in the pancreas, pituitary gland, and other endocrine organs, resulting in one or more of the following manifestations of endocrine dysfunction.</p><p class="headingAnchor" id="H3479085784"><span class="h4">Diabetes mellitus</span><span class="headingEndMark"> — </span>Pancreatic iron overload can lead to type 2 diabetes mellitus (DM). It appears that iron deposition is relatively selective for pancreatic beta cells (the insulin- and C-peptide-secreting cells); pancreatic alpha cell function (glucagon secretion) seems relatively intact [<a href="#rid58">58,59</a>]. Type 2 DM in combination with skin discoloration led to the past designation of individuals with HH as having "bronze diabetes."</p><p>DM has been reported in as many as 50 percent of patients with HH who present with symptoms. However, the baseline prevalence of type 2 DM is high in the general population, and a study that screened for HH in a population of 220 individuals with DM did not find an increased incidence of HH compared with 220 age- and sex-matched controls [<a href="#rid60">60</a>]. </p><p class="headingAnchor" id="H3196024938"><span class="h4">Hypopituitarism, hypogonadism, and hypothyroidism</span><span class="headingEndMark"> — </span>Pituitary iron deposition can cause hypopituitarism with reduced production of trophic hormones for several endocrine organs, leading to secondary hypogonadism or hypothyroidism. In some cases, these changes can be reversed with treatment, especially if instituted early in the disease course [<a href="#rid61">61-64</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary hypogonadism</strong> – Secondary hypogonadism with low testosterone can lead to decreased libido and impotence in males [<a href="#rid61">61,65-68</a>]. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p></p><p class="bulletIndent1">Amenorrhea can occur in females but appears to be much less common than hypogonadism in males. In one series of individuals with homozygous HH, none of the females had loss of libido or early menopause, whereas 10 of 41 males (24 percent) had low libido [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">Hypogonadism may also contribute to low bone density [<a href="#rid69">69</a>]. (See <a class="local">'Arthropathy'</a> below and  <a class="medical medical_review" href="/d/html/5618.html" rel="external">"Arthritis and bone disease associated with hereditary hemochromatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary hypothyroidism</strong> – Secondary hypothyroidism has been reported. In one study involving 49 individuals with homozygous HH, three were hypothyroid and had concomitant antithyroid antibodies [<a href="#rid70">70</a>]. One was hyperthyroid. All of the affected individuals were male; all 15 females in the series had normal thyroid function. (See  <a class="medical medical_review" href="/d/html/7861.html" rel="external">"Infiltrative thyroid disease", section on 'Hereditary hemochromatosis'</a>.)</p><p></p><p class="headingAnchor" id="H4054944997"><span class="h3">Central nervous system</span><span class="headingEndMark"> — </span>HH has been associated with generalized cognitive impairment as well as specific neurologic abnormalities [<a href="#rid71">71</a>]. A 2022 brain MRI study reported increased iron in the brain of individuals homozygous for <em>HFE</em> C282Y, but the significance is uncertain, and autopsy case series have not reported the same finding [<a href="#rid72">72</a>].</p><p>Homozygosity for the<em> HFE</em> H63D variant appears to be associated with an increased risk of amyotrophic lateral sclerosis (ALS). In a large meta-analysis of observational studies (over 66,000 cases and over 226,000 controls), the OR for ALS in H63D/H63D homozygotes was 3.9 (95% CI 1.2-13) [<a href="#rid73">73</a>]. </p><p class="headingAnchor" id="H3585929985"><span class="h3">Arthropathy</span><span class="headingEndMark"> — </span>HH can be associated with an arthropathy that causes symptoms of arthritis, arthralgias, and radiologic findings indistinguishable from calcium pyrophosphate crystal deposition disease. Joints in the hands are often affected  (<a class="graphic graphic_diagnosticimage graphicRef78740" href="/d/graphic/78740.html" rel="external">image 1</a>). The mechanism remains unclear, as does the predilection for the second and third metacarpophalangeal joints. (See  <a class="medical medical_review" href="/d/html/5618.html" rel="external">"Arthritis and bone disease associated with hereditary hemochromatosis", section on 'Clinical features'</a>.)</p><p>In contrast to many other manifestations of HH, reports from the 1990s suggested that iron removal was less effective for reversing the disease process in HH-associated arthropathy [<a href="#rid74">74</a>]. However, these findings likely reflected relatively late intervention in the disease process, and earlier intervention may be more effective.</p><p>The clinical presentation, evaluation, and management are discussed separately. (See  <a class="medical medical_review" href="/d/html/5618.html" rel="external">"Arthritis and bone disease associated with hereditary hemochromatosis"</a>.)</p><p class="headingAnchor" id="H2332474465"><span class="h3">Bronze skin</span><span class="headingEndMark"> — </span>Skin hyperpigmentation reflects a combination of iron deposition and melanin. The classic triad of cirrhosis, DM, and skin pigmentation ("bronze diabetes") typically occurs after the total-body iron content has reached as much as 20 grams.</p><p class="headingAnchor" id="H3170435603"><span class="h2">Susceptibility to infection</span><span class="headingEndMark"> — </span>Patients with iron overload, including those with HH, are at risk for infection with bacteria whose virulence is increased in the presence of excess iron; these are referred to as siderophilic bacteria [<a href="#rid75">75,76</a>]. </p><p>Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Yersinia enterocolitica</em></strong> – <em>Yersinia enterocolitica</em> is a gram-negative organism carried by wildlife and domestic livestock; transmission to humans is mostly foodborne. Typical symptoms include right lower quadrant abdominal pain, fever, vomiting, and diarrhea. Systemic infections including sepsis and liver abscesses have been reported in individuals with HH [<a href="#rid77">77-81</a>]. (See  <a class="medical medical_review" href="/d/html/3139.html" rel="external">"Yersiniosis: Infection due to Yersinia enterocolitica and Yersinia pseudotuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Vibrio vulnificus</em></strong> – <em>Vibrio vulnificus</em> is a gram-negative organism commonly associated with fish, crustaceans, and mollusks. Infection can be especially severe in individuals with HH. Systemic infection (sepsis) after ingestion of uncooked seafood and wound infection after exposure of skin wounds to seawater have both been reported [<a href="#rid82">82,83</a>]. It has been recommended that patients with HH avoid eating uncooked seafood [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/3128.html" rel="external">"Vibrio vulnificus infection"</a>.)</p><p></p><p>Other infectious organisms such as <em>Listeria monocytogenes </em>may also have increased pathogenesis in individuals with HH [<a href="#rid85">85-87</a>].</p><p>Infectious risk may be further increased if the individual is treated with the iron chelator <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a>, since the deferoxamine-iron chelate (feroxamine) can further stimulate bacterial growth; however, most individuals with HH are treated with phlebotomy rather than with iron chelation. (See  <a class="medical medical_review" href="/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects", section on 'Risk of infection'</a>.)</p><p>Although data are limited, the risk of these infections appears to be only in individuals with iron overload (ie, the risk does not appear to apply to those with an <em>HFE</em> C282Y/C282Y genotype who do not have iron overload).</p><p class="headingAnchor" id="H274061872"><span class="h2">Cancer risk</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCC</strong> – HH-associated hepatic iron overload confers an increased risk of hepatocellular cancer (HCC) and possibly other liver tumors such as cholangiocarcinoma (intrahepatic bile duct carcinoma). (See <a class="local">'Hepatic iron overload'</a> above.)</p><p></p><p class="bulletIndent1">Studies have demonstrated and quantified the risk, which is especially high in individuals with cirrhosis; estimates of the magnitude of risk ranging from 20- to 200-fold above that in the general population [<a href="#rid88">88-93</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A database study that evaluated outcomes in over 450,000 individuals who had <em>HFE</em> genetic testing found a 10-fold increased risk of liver cancers in C282Y homozygotes [<a href="#rid93">93</a>]. Of the 20 liver cancers, 14 were HCC and 5 were cholangiocarcinoma. The diagnosis of HH had been made in approximately one-half of the individuals at the time liver cancer was diagnosed. The lifetime risk (to age 75) for liver cancer was 7.2 percent (95% CI 3.9-13.1 percent), versus 0.6 percent for controls. The risk for liver cancer in female C282Y homozygotes did not reach a statistically significant increase. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A large population-based study estimated that the risk was increased approximately 20-fold over the general population risk (95% CI 16-22-fold) [<a href="#rid92">92</a>]. The risk was greatest in men and was not increased among first-degree relatives. </p><p></p><p class="bulletIndent1">These findings support the practice of screening for HCC in individuals with HH who have advanced liver fibrosis (stage 3 or stage 4 [cirrhosis]). (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis", section on 'Screening for HCC and other complications'</a> and  <a class="medical medical_review" href="/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other tumors</strong> – Meta-analyses of observational studies and large series have suggested increased risks of other cancer types such as colorectal or breast cancer in individuals homozygous for <em>HFE</em> C282Y, but the implications for clinical practice are unclear [<a href="#rid94">94,95</a>]. Smaller series have suggested increased risks of a variety of other cancers [<a href="#rid91">91,96-100</a>]. It is possible these observations reflect increased medical interactions rather than a true increase in the risk of other tumor types, although it is also possible that iron overload is a risk factor for cancer in other tissues. We ensure routine preventive care (avoiding smoking, maintaining a healthy weight) and perform appropriate cancer screening for these individuals, but we do not use more intensive screening for individuals with HH or <em>HFE</em> C282Y. (See  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1411966203"><span class="h2">Findings in heterozygous individuals</span><span class="headingEndMark"> — </span>Clinical manifestations of iron overload appear to be rare in individuals who are heterozygous for <em>HFE</em> C282Y (or other <em>HFE</em> variants). (See <a class="local">'Genotype-phenotype correlations'</a> above.)</p><p>If an individual heterozygous for <em>HFE</em> C282Y develops significant iron overload, evaluation for other contributing factors can be helpful. As an example, additional genetic analyses including sequencing of <em>HFE</em> (to detect rare deletions) and of other genes such as <em>HJV</em>, <em>HAMP</em>, <em>TFR2</em>, and <em>SLC40A1</em> may reveal other variants contributing to the clinical phenotype. Several cases of hemochromatosis due to digenic inheritance have been reported, leading to inclusion of this category in the novel classification proposed by BIOIRON [<a href="#rid1">1,101</a>]. These advanced molecular tests are available only at few referral centers, they require interpretation by experts in iron metabolism, and they are often time-consuming. Thus, they should not delay treatment in patients with proven iron overload.</p><p>Evidence of increased iron absorption has occasionally been reported in heterozygous individuals, but the significance is unclear. As an example, one series identified 1058 individuals who were heterozygous for <em>HFE</em> C282Y; they had relatives with homozygous HH [<a href="#rid102">102</a>]. Of the heterozygous individuals, 22 of 505 males (4 percent) and 44 of 553 females (8 percent) had elevated transferrin saturation (TSAT) values. In nearly all of these individuals, repeat testing after an overnight fast did not confirm the high TSAT value. Further, a similar proportion of controls (relatives who were not heterozygous for HH) had high TSAT values, suggesting that the high TSAT may have been unrelated to heterozygosity for the <em>HFE</em> variant. Liver biopsies were performed in 39 participants; six showed hepatic damage, but five of these individuals had an associated condition (excess alcohol, porphyria) that could have been responsible. Indications for testing are discussed below. (See <a class="local">'Indications for testing'</a> below and <a class="local">'Asymptomatic first-degree relatives'</a> below.)</p><p class="headingAnchor" id="H2250461949"><span class="h2">Natural history and reversibility of iron overload complications</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis", section on 'Evidence for efficacy'</a> and  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H3730545"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H2672738894"><span class="h2">Indications for testing</span><span class="headingEndMark"> — </span>We have a low threshold for performing initial laboratory testing for HH with iron studies if the diagnosis is suspected  (<a class="graphic graphic_algorithm graphicRef121495" href="/d/graphic/121495.html" rel="external">algorithm 1</a>). Identifying HH is important because treatment is highly effective and safe and can prevent virtually all of the disease complications if instituted before significant iron overload has occurred. (See <a class="local">'Initial testing with iron studies'</a> below.) </p><p>We generally reserve genetic testing for individuals with iron overload or the first-degree relatives of individuals with iron overload or known HH disease variants. (See <a class="local">'HFE genetic testing'</a> below.)</p><p>HH may be suspected in individuals with any of the following [<a href="#rid103">103,104</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained fatigue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical signs or symptoms suggestive of iron overload, which are discussed in more detail above (see <a class="local">'Manifestations of organ iron overload'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic liver disease or cirrhosis</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac enlargement, heart failure, or conduction defects</p><p class="bulletIndent2"><span class="glyph">•</span>Type 2 diabetes mellitus</p><p class="bulletIndent2"><span class="glyph">•</span>Hypogonadism, decreased libido, or male sexual dysfunction</p><p class="bulletIndent2"><span class="glyph">•</span>Skin hyperpigmentation</p><p class="bulletIndent2"><span class="glyph">•</span>Arthropathy, especially involving the second and third metacarpophalangeal joints</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Porphyria cutanea tarda (PCT; the most common cutaneous porphyria), which is sensitive to body iron levels</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A first- or second-degree relative diagnosed with HH or found to have the <em>HFE</em> C282Y variant (generally deferred to adulthood unless symptomatic) (see <a class="local">'Asymptomatic first-degree relatives'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory test results that may be associated with HH:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained liver function test abnormalities</p><p class="bulletIndent2"><span class="glyph">•</span>High serum ferritin (eg, &gt;300 ng/mL in males or postmenopausal females; &gt;200 ng/mL in premenopausal females)</p><p class="bulletIndent2"><span class="glyph">•</span>High transferrin saturation (TSAT; eg, &gt;45 percent)</p><p></p><p>Additional information on cutoff values in different guidelines is discussed below. (See <a class="local">'Initial testing with iron studies'</a> below.)</p><p>The more widespread use of genetic testing and iron studies increases the likelihood that testing will be performed on individuals who are clinically asymptomatic or are at a much earlier stage of disease than seen before the 1990s. These individuals may have abnormal laboratory results suggestive of HH as an incidental finding or as part of the evaluation for another condition.</p><p>Population screening in asymptomatic individuals without any of these indications for testing is discussed separately. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Role of population screening'</a>.) </p><p class="headingAnchor" id="H1965924546"><span class="h2">Initial testing with iron studies</span><span class="headingEndMark"> — </span>Iron studies are the initial test used to determine whether there is clinical evidence of iron overload  (<a class="graphic graphic_algorithm graphicRef121495" href="/d/graphic/121495.html" rel="external">algorithm 1</a>). Even in an individual with known biallelic C282Y variants in the <em>HFE </em>gene, iron studies are needed because the disease penetrance is low (many individuals who are homozygous for <em>HFE</em> C282Y will not have clinical iron overload). </p><p>Some individuals with suspected HH will know their <em>HFE</em> genotype before they know the results of their iron studies. However, absence of the common <em>HFE </em>C282Y variant is not a reason to omit iron studies in an individual with suspected iron overload, as there may be other causes of iron overload, either genetic or acquired. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Non-HFE hemochromatosis'</a> and  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Causes of iron overload'</a>.)</p><p>Routine iron studies include serum iron, serum transferrin (also sometimes reported as total iron binding capacity [TIBC]), TSAT, and serum ferritin level. If only one of these results is available, a complete panel should be obtained. </p><p>Experts differ slightly in the thresholds above which they are concerned about excess iron stores and whether they repeat testing in all cases. We generally prefer the lower thresholds, but clinicians may choose to use other values or to follow institutional guidelines that may be more appropriate for the local population. If there is concern about iron overload, testing can be repeated or additional testing can be performed such as liver function tests and/or <em>HFE</em> genetic testing. If a higher threshold is used, it may be reasonable to repeat the testing in six months to a year, as individuals with HH will continue to accumulate iron and their ferritin levels will continue to increase. If there is concern about iron overload in either case, proceeding to magnetic resonance imaging (MRI) is reasonable (see <a class="local">'MRI'</a> below) since ferritin is too closely linked to inflammation, and MRI is the more definitive means of assessing iron overload.</p><p>The following summarizes values used in a 2019 guideline from the American College of Gastroenterology (ACG), a 2018 guideline from the British Society for Haematology (BSH), a 2011 guideline from the American Association for the Study of Liver Disease (AASLD), a 2022 guideline from the European Association for the Study of Liver Disease (EASL), a 2022 recommendation from BIOIRON (the International Society for the Study of Iron in Biology and Medicine), and a 2005 guideline from the American College of Physicians (ACP) [<a href="#rid24">24,103-105</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TSAT</strong> – A TSAT indicative of excess iron stores has been set at:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACG: ≥45 percent</p><p class="bulletIndent2"><span class="glyph">•</span>BSH: &gt;40 percent for females and &gt;50 percent for males</p><p class="bulletIndent2"><span class="glyph">•</span>AASLD: ≥45 percent</p><p class="bulletIndent2"><span class="glyph">•</span>ACP: &gt;55 percent</p><p class="bulletIndent2"><span class="glyph">•</span>EASL: &gt;45 percent</p><p class="bulletIndent2"><span class="glyph">•</span>BIOIRON: &gt;45 percent</p><p></p><p>TSAT is the ratio of iron to TIBC (TSAT = serum iron ÷ TIBC x 100). It can also be calculated as the ratio between serum iron and transferrin multiplied by the correction factor 1.42 (TSAT = serum iron [mcg/dL] ÷ transferrin [g/dL] x 1.42). </p><p>Because TSAT is a ratio, it can be increased if the serum iron is higher or if the TIBC or transferrin is lower. Thus, TSAT can be falsely elevated by conditions that acutely raise the serum iron level such as an episode of hemolysis or ingestion of an oral iron tablet. Similarly, conditions lowering the transferrin, such as liver cirrhosis due to other causes, may also result in increased TSAT not due to hemochromatosis.  </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ferritin</strong> – A ferritin indicative of excess iron stores has been set at:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACG: &gt;300 ng/mL (&gt;300 mcg/L) for males and postmenopausal females, &gt;200 ng/mL for premenopausal females</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BSH, BIOIRON, EASL, and ACP: &gt;300 ng/mL for males, &gt;200 ng/mL for females</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AASLD: &gt;200 ng/mL for males and &gt;150 ng/mL for females or above the upper limit of normal for the testing laboratory</p><p></p><p class="bulletIndent1">Ferritin is the circulating iron storage protein. It is made in the liver. Ferritin is also an acute phase reactant, and levels can fluctuate. Ferritin it can be elevated by chronic inflammation, acute liver injury, or certain other acute illnesses like HIV infection or hemophagocytic lymphohistiocytosis (HLH). (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">If there is any question about the interpretation of a high ferritin level, we rely on MRI as an excellent indicator of hepatic and/or cardiac iron levels. (See <a class="local">'MRI'</a> below.)</p><p></p><p>For individuals with evidence of excess iron stores based on these thresholds and homozygosity for the <em>HFE</em> C282Y variant, additional testing may be indicated to determine tissue iron levels (see <a class="local">'Estimation of iron stores'</a> below); management (typically with phlebotomy) is discussed separately. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p>Some experts use fasting blood samples for these measurements [<a href="#rid104">104</a>]. One study showed no improvement in sensitivity or specificity in the detection of C282Y homozygotes when fasting samples are obtained [<a href="#rid106">106</a>]. However, the 2011 AASLD guidelines state that it is advisable to confirm an elevated TSAT with a second determination; it is not unreasonable to do this on a fasting specimen [<a href="#rid24">24</a>]. </p><p>Additional information about iron studies in other causes of iron overload is presented separately. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'CBC, LFTs, and iron studies'</a>.)</p><p>Iron studies (or ferritin alone) are also monitored during therapy and used to assess response to iron removal. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p class="headingAnchor" id="H3056884777"><span class="h2">Liver function tests</span><span class="headingEndMark"> — </span>Liver function tests (transaminases, bilirubin, alkaline phosphatase, prothrombin time/international normalized ratio [PT/INR], albumin) are appropriate in any individual with suspected HH. This includes individuals with evidence of iron overload on iron studies, those with symptoms of HH who do not have evidence of iron overload, and/or those with other findings suggestive of liver disease such as ascites, splenomegaly, or mild cytopenias.</p><p>Elevated transaminases typically signify liver injury but they are not specific for HH. Results should be evaluated together with other testing for the presence and severity of iron overload (iron studies, MRI), <em>HFE</em> genetic testing, and testing for other potential causes of liver disease.</p><p>Interpretation of results and appropriate evaluations for other causes of liver injury are discussed separately. (See  <a class="medical medical_review" href="/d/html/3573.html" rel="external">"Overview of liver biochemical tests"</a> and  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p class="headingAnchor" id="H1114869010"><span class="h2"><i>HFE </i>genetic testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for testing</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Documented iron overload</strong> – Testing for the two common <em>HFE</em> variants, C282Y and H63D, is appropriate in any individual with evidence of iron overload (eg, from iron studies). (See <a class="local">'Initial testing with iron studies'</a> above and <a class="local">'Asymptomatic first-degree relatives'</a> below.)</p><p></p><p class="bulletIndent2">Genetic testing may be particularly useful in patients with liver disease and suspected iron overload (based on iron studies), as HH may be contributing to the severity of another condition. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Porphyria cutanea tarda</strong> – <em>HFE</em> genetic testing is also appropriate for those known to have porphyria cutanea tarda (PCT), which is exacerbated by iron overload and treated with phlebotomy to decrease iron stores in many cases. (See  <a class="medical medical_review" href="/d/html/7108.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis", section on 'HFE'</a> and  <a class="medical medical_review" href="/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Phlebotomy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First-degree relatives</strong> – <em>HFE</em> testing is often appropriate in first-degree relatives of individuals with <em>HFE</em> C282Y, especially if the affected individual has evidence of iron overload. Testing in asymptomatic relatives is discussed below. (See <a class="local">'Asymptomatic first-degree relatives'</a> below.)</p><p></p><p class="bulletIndent1">In contrast to these indications, <em>HFE</em> genetic testing is generally not done in individuals with liver disease without iron overload or in the general population. Population screening is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Role of population screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Incorporation of genetic test results into the evaluation is summarized in the figure  (<a class="graphic graphic_algorithm graphicRef121495" href="/d/graphic/121495.html" rel="external">algorithm 1</a>) and discussed below. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct-to-consumer testing</strong> – <em>HFE </em>genetic testing may also be included in certain gene panels or in direct-to-consumer genetic tests. (See  <a class="medical medical_review" href="/d/html/14599.html" rel="external">"Personalized medicine", section on 'Direct-to-consumer testing'</a>.)</p><p></p><p class="bulletIndent1">We do not advocate routine genetic testing in individuals without a family history of HH or evidence of iron overload [<a href="#rid107">107</a>]. </p><p></p><p class="bulletIndent1">If an individual receives a test report of an HH variant from an unrelated gene panel or direct-to-consumer test, the testing should be repeated by a certified laboratory before an extensive evaluation is undertaken. Likewise, testing should be repeated in a certified laboratory if an individual with suspected HH based on family history or iron studies receives a negative report from an unrelated gene panel or direct-to-consumer test. (See  <a class="medical medical_review" href="/d/html/123113.html" rel="external">"Gene test interpretation: <i>HFE</i> (hereditary hemochromatosis gene)", section on 'How to read the report'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other genes</strong> – Pathogenic variants affecting genes other than <em>HFE</em> leading to iron overload have been identified  (<a class="graphic graphic_table graphicRef56329" href="/d/graphic/56329.html" rel="external">table 1</a>), although these are rare compared to <em>HFE</em> variants. It is reasonable to test for variants in other genes in the rare patient with iron overload who tests negative for <em>HFE</em> variants and does not have the more common other causes for iron overload. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Non-HFE hemochromatosis'</a> and  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Causes of iron overload'</a>.)</p><p></p><p class="headingAnchor" id="H2354289094"><span class="h2">Estimation of iron stores</span><span class="headingEndMark"> — </span>Higher ferritin levels are generally associated with higher organ iron, but the correlation between absolute levels is weak. It is appropriate to use a more accurate method to obtain an estimate of iron deposition in the liver and/or heart. We generally obtain such a measure if the serum ferritin level is &gt;800 to 1000 ng/mL (&gt;800 to 1000 mcg/L), or if there is evidence of liver injury (elevated transaminases, hepatomegaly) or cardiac injury (heart failure, arrhythmia).</p><p class="headingAnchor" id="H30312445"><span class="h3">MRI</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is a noninvasive approach to estimating body iron stores; it can be performed on liver, heart, or in a combined scan of liver and heart. MRI of one or both organs is appropriate in most individuals with a serum ferritin level &gt;800 to 1000 ng/mL (&gt;800 to 1000 mcg/L). A lower threshold could be considered in patients with unexplained hyperferritinemia after common causes of increased ferritin, such as nonalcoholic fatty liver disease (NAFLD) or excess alcohol, have been excluded. In such cases, the confirmation of hepatic iron overload with a normal TSAT may suggest a rare iron metabolism disorder such as aceruloplasminemia or ferroportin disease. (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Non-HFE hemochromatosis'</a>.)</p><p>The importance of MRI is greater in those suspected to have the most severe iron overload (those with very high ferritin or symptoms of organ injury). MRI may also be appropriate in individuals with lower ferritin levels for whom there is concern about organ injury (individuals with elevated liver function tests or symptoms of heart failure).</p><p>It is essential to discuss the goals of the testing with the radiology department prior to the MRI so that the appropriate studies are performed. Details about the use of MRI to assess tissue iron deposition are presented separately. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Noninvasive imaging (MRI)'</a>.)</p><p class="headingAnchor" id="H46351464"><span class="h3">Liver biopsy for selected patients</span><span class="headingEndMark"> — </span>Liver biopsy is not required for the diagnosis of HH, and it has been supplanted by MRI for estimation of iron stores in the majority of patients. (See <a class="local">'MRI'</a> above.)</p><p>However, liver biopsy provides additional information about liver histology and can be useful for assessing the extent of fibrosis and presence of cirrhosis, as well as other causes of liver disease that may be contributing to liver injury in patients with HH. Thus, liver biopsy may be appropriate in challenging cases in which more than one cause of liver disease is suspected or the extent of fibrosis is difficult to determine. If available, ultrasound-based elastography can be used as a noninvasive means of assessing the need for liver biopsy. (See  <a class="medical medical_review" href="/d/html/96717.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography"</a>.)</p><p>We generally reserve liver biopsy for the following situations in which histologic assessment would be helpful in management:</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with evidence of iron overload (high TSAT and ferritin; evidence of iron overload on MRI) for whom <em>HFE</em> genetic testing is negative. As noted separately, some of these individuals have a variant in a non-<em>HFE</em> gene (see  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>); for others (often African American males) the relevant genetic variant may not have been identified yet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with possible hepatic fibrosis and/or cirrhosis, such as those with a ferritin &gt;800 to 1000 ng/mL (&gt;800 to 1000 mcg/L) and/or elevations of liver enzymes (any elevation in alanine aminotransferase [ALT]), for whom additional testing for complications (varices, hepatocellular cancer) may also be indicated. In these individuals, the liver biopsy might provide prognostic information rather than being used for the diagnosis itself.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals for whom another cause of liver disease is suspected, such as excess alcohol, NAFLD, or hepatitis C, for whom other therapies may be appropriate.</p><p></p><p>In a series of 182 individuals with HH who had iron studies and liver biopsy, only 1 of 93 with a ferritin &lt;1000 ng/mL had evidence of cirrhosis, compared with 39 of 89 with a ferritin &gt;1000 ng/mL (1 percent versus 44 percent) [<a href="#rid108">108</a>]. In a multivariate model that adjusted for age and liver enzymes, the probability of cirrhosis was 7 percent in those with a ferritin &lt;1000 ng/mL and 72 percent in those with a ferritin &gt;1000 ng/mL. </p><p>The 2011 AASLD guideline recommends liver biopsy only in C282Y homozygotes or C282Y/H63D compound heterozygotes who have elevated liver enzymes or a ferritin &gt;1000 ng/mL [<a href="#rid24">24</a>]. The 2018 BSH guideline uses a similar approach, along with transient elastography as a tool to select patients who may require liver biopsy [<a href="#rid103">103</a>]. </p><p>The 2022 European Association for the Study of the Liver (EASL) practice guidelines on hemochromatosis recommend liver biopsy as an option to assess liver cirrhosis or fibrosis when the ferritin is &gt;1000 ng/mL, unless the clinical picture of cirrhosis is otherwise clear or fibrosis can be demonstrated non-invasively by transient elastography [<a href="#rid109">109</a>]. </p><p>Histopathologic features and grading of liver iron content from biopsy specimens is discussed separately. (See  <a class="medical medical_review" href="/d/html/3614.html" rel="external">"Methods to determine hepatic iron content"</a>.)</p><p class="headingAnchor" id="H1713383602"><span class="h3">Mobilized iron</span><span class="headingEndMark"> — </span>In individuals with iron indices indicative of classical HH with iron overload, we initiate phlebotomy therapy. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.) </p><p>Iron mobilized by well-controlled phlebotomy can provide a surrogate for total body iron analogous to liver iron quantitation [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H3730936"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of HH is made easily in an individual with iron overload and homozygosity for <em>HFE</em> C282Y  (<a class="graphic graphic_algorithm graphicRef121495" href="/d/graphic/121495.html" rel="external">algorithm 1</a>). (See <a class="local">'Initial testing with iron studies'</a> above.)</p><p>Individuals who have iron overload and are compound heterozygous with C282Y/H63D should be accurately investigated (and treated) for other causes of liver disease since this genotype is not generally associated with clinically relevant iron overload. </p><p>The diagnosis of HH can be reliably excluded if an individual does not have iron overload and lacks the <em>HFE</em> C282Y variant (or variant in another iron overload gene, in rare cases of non-<em>HFE</em> HH). </p><p>For individuals with biallelic <em>HFE</em> C282Y who do not have iron overload (this represents the vast majority [at least 80 percent] of people with biallelic <em>HFE</em> C282Y), we do not diagnose them with HH, but we do inform them of their genotype and phenotype, as discussed above (see <a class="local">'Terminology'</a> above). We follow these individuals with a yearly ferritin level, and we only intervene if iron overload develops.</p><p>There may be diagnostic uncertainty in intermediate cases, such as individuals who are homozygous for<em> HFE</em> H63D. </p><p class="bulletIndent1"><span class="glyph">●</span>If these individuals have iron overload (as evidenced by iron studies and/or MRI), we treat them accordingly. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If these individuals have a high ferritin level due to another cause of liver disease such as viral hepatitis, NAFLD, and/or alcohol use (typically, ferritin in these cases is &lt;1000 ng/mL), we do not diagnose them with HH. This includes individuals with heterozygosity for <em>HFE </em>C282Y who have a high ferritin level due to another condition. Ideally, these individuals are treated for the underlying cause of their high ferritin and an improvement is documented. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults"</a> and  <a class="medical medical_review" href="/d/html/3611.html" rel="external">"Management of alcohol-associated steatosis and alcohol-associated cirrhosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If these individuals do not have iron overload, we do not diagnose them with HH, but we do inform them of their genotype, follow them with a yearly ferritin level, and only intervene if iron overload develops. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="headingAnchor" id="H59526730"><span class="h2">Asymptomatic first-degree relatives</span><span class="headingEndMark"> — </span>Testing is appropriate for any first-degree relative of an individual diagnosed with HH. </p><p>It is generally appropriate to delay testing until adulthood, when informed consent can be given. Iron overload rarely becomes clinically significant until late adulthood. (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing", section on 'Testing children'</a>.)</p><p>Testing of these individuals includes iron studies to determine whether there is iron overload, in addition to <em>HFE</em> genetic testing. The presence of the C282Y variant may affect future monitoring and/or genetic testing and counseling of children (when they reach adulthood).</p><p>For those with biallelic <em>HFE</em> C282Y or other HH genotypes, we repeat iron studies periodically, along with other routine clinical care (annually for a male over age 40 or a postmenopausal female, with less frequent testing if results are repeatedly normal, or once in later life for an individual who was initially tested when younger than 40 years [male] or when premenopausal [female]).</p><p>For those who undergo genetic testing, it is ideal to know the proband's <em>HFE</em> genotype to test for the familial variant(s); however, in practice, the vast majority of individuals with HH will have the C282Y variant. (See <a class="local">'HFE gene variants'</a> above.)</p><p class="headingAnchor" id="H3731275"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of HH includes other causes of iron overload and other chronic conditions that may be associated with increased serum ferritin. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalassemia</strong> – Thalassemia is an inherited disorder in which ineffective erythropoiesis leads to anemia and increased iron absorption. This can lead to clinically relevant iron overload in patients with thalassemia major (where chronic transfusions represent the main driver), and especially in those with thalassemia intermedia, while this occurs rarely in individuals with a thalassemia trait [<a href="#rid111">111</a>]. Like HH, thalassemia is heritable. Unlike HH, individuals with thalassemia generally have anemia and abnormalities of the red blood cell (RBC) indices such as microcytosis, and they generally present in childhood or early adulthood. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hereditary iron loading anemias</strong> – Many other primary RBC disorders (the so-called "iron loading anemias") may have an inherent risk of iron overload [<a href="#rid112">112,113</a>]. Like HH, these are heritable conditions with iron overload. Unlike HH, these disorders are typically associated with anemia and abnormal RBC indices [<a href="#rid1">1,114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusional iron overload</strong> – Transfusional iron overload is an acquired form of iron overload. Like HH, these individuals may develop a significant body iron burden. Unlike HH, they have a history of multiple transfusions (typically more than 10 to 20 transfusions), they lack biallelic <em>HFE</em> C282Y, and they typically require therapy with an iron-chelating agent rather than phlebotomy. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of liver disease</strong> – There are many causes of liver disease, and liver disease may have another cause instead of or in addition to HH. Like HH, individuals with other causes of liver disease may have abnormal liver function tests and high serum ferritin (an acute phase reactant and released from damaged hepatocytes). Unlike HH, other causes of liver disease generally do not cause a high transferrin saturation (TSAT) or evidence of excess hepatic iron deposition. An exception may be advanced liver diseases from other causes where the synthesis of transferrin is compromised, thereby affecting the formula for TSAT calculation. Excess alcohol use is especially important to elucidate because it may substantially exacerbate HH. Nonalcoholic fatty liver disease (NAFLD) is another common cause of ferritin elevation and elevated liver enzymes [<a href="#rid115">115</a>]. Determining whether a true iron overload state is also present can be challenging; MRI might also be helpful in such cases [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a> and  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of heart</strong> <strong>failure</strong> – There are many causes of heart failure, and not all individuals with an HH genotype and heart disease have cardiac iron overload. Like HH, individuals with other causes of heart failure may have a slightly elevated serum ferritin level (an acute phase reactant), but unlike HH, heart disease from other causes does not cause a high TSAT or evidence of cardiac iron overload. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of arthropathy</strong> – There are many causes of polyarthropathy, and not all individuals with an HH genotype and joint pain have joint iron overload. Like HH, individuals with other causes of arthropathy may have an elevated serum ferritin level (an acute phase reactant), but unlike HH, arthropathy from other causes does not cause a high TSAT and the radiologic patterns may differ. (See  <a class="medical medical_review" href="/d/html/1821.html" rel="external">"Evaluation of the adult with polyarticular pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions with high ferritin</strong> – Ferritin is an acute phase reactant made in the liver; it may be elevated in severe liver disease, HIV infection, or conditions such as hemophagocytic lymphohistiocytosis. Other rare causes of hyperferritinemia include (see  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Other causes of high ferritin'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary hyperferritinemia-cataract syndrome [<a href="#rid116">116</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Ferroportin disease [<a href="#rid117">117</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Aceruloplasminemia [<a href="#rid118">118</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Gaucher disease [<a href="#rid119">119</a>]</p><p></p><p class="bulletIndent1">Unlike HH, these individuals do not have biallelic<em> HFE</em> C282Y. They should be referred to a center with expertise in iron metabolism disorders. </p><p></p><p>Causes of iron overload other than HH are listed in the table  (<a class="graphic graphic_table graphicRef105365" href="/d/graphic/105365.html" rel="external">table 2</a>). Most of these should be clinically obvious, such as those disorders treated with multiple blood transfusions over long periods of time (aplastic anemia, thalassemia, myelodysplastic syndrome, sickle cell disease). (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Causes of iron overload'</a>.)</p><p>However, the most important differential diagnostic issue to be concerned with is whether the patient with HH is symptomatic because of the presence of a secondary cause for iron overload (excess alcohol use, NAFLD, other liver disease), and, vice versa, whether the patient with a secondary cause also has a genetic component contributing to iron overload. Since alcohol is one of the strongest exacerbating factors in HH, its use should always be suspected and appropriate inquiries made into quantitating the patient's intake of alcoholic beverages [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Causes of iron overload'</a>.)</p><p class="headingAnchor" id="H3075226001"><span class="h1">POST-DIAGNOSTIC TESTING</span><span class="headingEndMark"> — </span>It is important to evaluate for other causes of iron overload and/or organ injury, especially in younger individuals and those with genotypes other than <em>HFE</em> C282Y/C282Y. </p><p class="bulletIndent1"><span class="glyph">●</span>We ask about alcohol intake, travel history, and other exposures related to liver disease, and we test for viral hepatitis in individuals with elevated transaminases. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We often obtain a liver ultrasound to look for steatosis or other evidence of liver disease that may explain abnormalities in iron indices and liver enzymes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional testing after diagnosis, such as screening for hepatocellular cancer in individuals with HH-associated cirrhosis, is discussed separately. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Post-diagnostic testing'</a> and  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis", section on 'Treatment and prevention of comorbidities'</a>.)</p><p></p><p class="headingAnchor" id="H3843640398"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116616.html" rel="external">"Society guideline links: Hemochromatosis"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15875.html" rel="external">"Patient education: Hemochromatosis (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4573.html" rel="external">"Patient education: Hereditary hemochromatosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12535812"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Hereditary hemochromatosis (HH) is an inherited disorder in which most of the affected individuals are homozygous for the C282Y variant in the <em>HFE</em> gene  (<a class="graphic graphic_table graphicRef56329" href="/d/graphic/56329.html" rel="external">table 1</a>). This causes lifelong increased intestinal iron absorption, iron overload, and ultimately tissue damage. Homozygosity for C282Y accounts for approximately 90 percent of HH cases in White individuals of European ancestry; less common genotypes include variants in other genes  (<a class="graphic graphic_table graphicRef56329" href="/d/graphic/56329.html" rel="external">table 1</a>), collectively termed non-HFE hemochromatosis. (See <a class="local">'Terminology'</a> above and <a class="local">'Pathophysiology'</a> above and  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– HH is mainly seen in individuals with European ancestry, in whom it is one of the most common genetic disorders (gene frequency, 4 to 6 percent). Homozygosity for C282Y is seen in 1 in 150 to 1 in 300 individuals. There are no sex differences in the prevalence of C282Y, but males are more likely to develop severe iron overload and to present at a younger age. Only 1 in 10 individuals homozygous for <em>HFE</em> C282Y will develop iron overload (prevalence, 0.2 to 0.7 percent). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings</strong> – Clinical manifestations generally do not occur until &gt;40 years in males and after menopause in females. Nonspecific symptoms (fatigue, lethargy, apathy) are commonly reported, as are symptoms attributable to iron overload, especially in the liver, heart, and pituitary gland. Untreated, patients can develop cirrhosis, hepatocellular cancer (HCC), heart failure, arrhythmias, type 2 diabetes, hypogonadism, cognitive changes, arthropathy, and bronze-colored skin. Individuals with HH are increasingly being identified when asymptomatic. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect</strong> – Identifying HH is important because treatment is highly effective and safe and can prevent virtually all disease complications if instituted early. HH may be suspected in individuals with unexplained fatigue; symptoms of iron overload in specific organs; porphyria cutanea tarda (PCT); unexplained liver function test abnormalities; high ferritin or transferrin saturation (TSAT); or HH in a first-degree relative. (See <a class="local">'Indications for testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory testing</strong> – The initial test is usually iron studies  (<a class="graphic graphic_algorithm graphicRef121495" href="/d/graphic/121495.html" rel="external">algorithm 1</a>). TSAT ≥45 percent and/or ferritin &gt;300 ng/mL (&gt;300 mcg/L) in males or &gt;200 ng/mL (&gt;200 mcg/L) in females is consistent with iron overload (caveats discussed above). For those with iron overload, liver function tests and<em> HFE </em>genetic testing are appropriate. (See <a class="local">'Initial testing with iron studies'</a> above and <a class="local">'Liver function tests'</a> above and <a class="local">'HFE genetic testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tests for tissue iron overload</strong> – Magnetic resonance imaging (MRI) is generally used to quantify liver and/or cardiac iron if ferritin is &gt;1000 ng/mL (&gt;1000 mcg/L); lower ferritin threshold may be considered in certain cases, as discussed above. Liver biopsy is generally reserved for suspected hepatic fibrosis or cirrhosis. Mobilized iron may serve as a surrogate for body iron overload while also providing treatment. (See <a class="local">'Estimation of iron stores'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic confirmation</strong> – The diagnosis of HH is made in an individual with iron overload and homozygosity for<em> HFE</em> C282Y<em>.</em> The molecular diagnosis of non-HFE hemochromatosis can be challenging and available only at referral centers. This should not delay the appropriate treatment in individuals with an otherwise typical clinical picture.<em> </em>(See <a class="local">'Diagnostic criteria'</a> above and  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Non-HFE hemochromatosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic individuals</strong> – <em>HFE</em> testing is appropriate in individuals with a first-degree relative with HH, even if they do not have iron overload. (See <a class="local">'Asymptomatic first-degree relatives'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Population screening</strong> – (See  <a class="medical medical_review" href="/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes", section on 'Role of population screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> –<strong> </strong>The differential diagnosis includes other causes of iron overload and other conditions with increased ferritin. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-diagnostic testing and treatment</strong> – Other causes of iron overload and/or organ injury (alcohol, viral hepatitis) should be evaluated, especially in younger individuals and those with genotypes other than <em>HFE </em>C282Y/C282Y. Testing may be indicated after diagnosis, such as screening for HCC in individuals with HH-associated cirrhosis. Management of HH is discussed separately. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="headingAnchor" id="H2690554605"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges the extensive contributions of Bruce R Bacon, MD, and William C Mentzer, MD, to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Girelli D, Busti F, Brissot P, et al. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 2022; 139:3018.</a></li><li><a class="nounderline abstract_t">Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13:399.</a></li><li><a class="nounderline abstract_t">Pietrangelo A. Genetics, Genetic Testing, and Management of Hemochromatosis: 15 Years Since Hepcidin. Gastroenterology 2015; 149:1240.</a></li><li><a class="nounderline abstract_t">Nandar W, Connor JR. HFE gene variants affect iron in the brain. J Nutr 2011; 141:729S.</a></li><li><a class="nounderline abstract_t">McLaren GD, Gordeuk VR. Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Hematology Am Soc Hematol Educ Program 2009; :195.</a></li><li><a class="nounderline abstract_t">Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352:1769.</a></li><li><a class="nounderline abstract_t">Moirand R, Jouanolle AM, Brissot P, et al. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999; 116:372.</a></li><li><a class="nounderline abstract_t">Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006; 4:1403.</a></li><li><a class="nounderline abstract_t">Kelley M, Joshi N, Xie Y, Borgaonkar M. Iron overload is rare in patients homozygous for the H63D mutation. Can J Gastroenterol Hepatol 2014; 28:198.</a></li><li><a class="nounderline abstract_t">Adams PC, Jeffrey G, Ryan J. Haemochromatosis. Lancet 2023; 401:1811.</a></li><li><a class="nounderline abstract_t">Hollerer I, Bachmann A, Muckenthaler MU. Pathophysiological consequences and benefits of HFE mutations: 20 years of research. Haematologica 2017; 102:809.</a></li><li><a class="nounderline abstract_t">Distante S, Robson KJ, Graham-Campbell J, et al. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004; 115:269.</a></li><li><a class="nounderline abstract_t">Hermine O, Dine G, Genty V, et al. Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. Biochimie 2015; 119:1.</a></li><li><a class="nounderline abstract_t">Cairo G, Recalcati S, Montosi G, et al. Inappropriately high iron regulatory protein activity in monocytes of patients with genetic hemochromatosis. Blood 1997; 89:2546.</a></li><li><a class="nounderline abstract_t">Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood 2016; 127:2809.</a></li><li><a class="nounderline abstract_t">Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica 2020; 105:260.</a></li><li><a class="nounderline abstract_t">Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician 2013; 87:183.</a></li><li><a class="nounderline abstract_t">Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993; 328:1616.</a></li><li><a class="nounderline abstract_t">Pippard MJ. Detection of iron overload. Lancet 1997; 349:73.</a></li><li><a class="nounderline abstract_t">Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318:1355.</a></li><li><a class="nounderline abstract_t">Niederau C, Niederau CM, Lange S, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998; 128:337.</a></li><li><a class="nounderline abstract_t">Wallace DF, Subramaniam VN. The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. Genet Med 2016; 18:618.</a></li><li><a class="nounderline abstract_t">Koshy A, Mukkada RJ, Chettupuzha AP, et al. Hemochromatosis in India: First Report of Whole Exome Sequencing With Review of the Literature. J Clin Exp Hepatol 2020; 10:163.</a></li><li><a class="nounderline abstract_t">Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328.</a></li><li><a class="nounderline abstract_t">Grosse SD, Gurrin LC, Bertalli NA, Allen KJ. Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Genet Med 2018; 20:383.</a></li><li><a class="nounderline abstract_t">Cherfane CE, Hollenbeck RD, Go J, Brown KE. Hereditary hemochromatosis: missed diagnosis or misdiagnosis? Am J Med 2013; 126:1010.</a></li><li><a class="nounderline abstract_t">Gasser B, Courtois F, Hojjat-Assari S, et al. [Hereditary hemochromatosis: presenting manifestations and diagnostic delay]. Rev Med Interne 2014; 35:160.</a></li><li><a class="nounderline abstract_t">Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343:1529.</a></li><li><a class="nounderline abstract_t">Pilling LC, Tamosauskaite J, Jones G, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ 2019; 364:k5222.</a></li><li><a class="nounderline abstract_t">Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991; 90:445.</a></li><li><a class="nounderline abstract_t">Niederau C, Strohmeyer G, Stremmel W. Epidemiology, clinical spectrum and prognosis of hemochromatosis. Adv Exp Med Biol 1994; 356:293.</a></li><li><a class="nounderline abstract_t">Tamosauskaite J, Atkins JL, Pilling LC, et al. Hereditary Hemochromatosis Associations with Frailty, Sarcopenia and Chronic Pain: Evidence from 200,975 Older UK Biobank Participants. J Gerontol A Biol Sci Med Sci 2019; 74:337.</a></li><li><a class="nounderline abstract_t">Mohammad A, Carey JJ, Storan E, et al. High prevalence of fibromyalgia in patients with HFE-related hereditary hemochromatosis. J Clin Gastroenterol 2013; 47:559.</a></li><li><a class="nounderline abstract_t">Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44:472.</a></li><li><a class="nounderline abstract_t">Ye Q, Qian BX, Yin WL, et al. Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. PLoS One 2016; 11:e0163423.</a></li><li><a class="nounderline abstract_t">Wood MJ, Powell LW, Dixon JL, Ramm GA. Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus. Hepatology 2012; 56:904.</a></li><li><a class="nounderline abstract_t">Irving MG, Halliday JW, Powell LW. Association between alcoholism and increased hepatic iron stores. Alcohol Clin Exp Res 1988; 12:7.</a></li><li><a class="nounderline abstract_t">Diwakaran HH, Befeler AS, Britton RS, et al. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002; 36:687.</a></li><li><a class="nounderline abstract_t">Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50:248.</a></li><li><a class="nounderline abstract_t">Girelli D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009; 51:845.</a></li><li><a class="nounderline abstract_t">Olson LJ, Edwards WD, McCall JT, et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987; 10:1239.</a></li><li><a class="nounderline abstract_t">Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation 2011; 124:2253.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1994. A 25-year-old man with the recent onset of diabetes mellitus and congestive heart failure. N Engl J Med 1994; 331:460.</a></li><li><a class="nounderline abstract_t">Rivers J, Garrahy P, Robinson W, Murphy A. Reversible cardiac dysfunction in hemochromatosis. Am Heart J 1987; 113:216.</a></li><li><a class="nounderline abstract_t">Easley RM Jr, Schreiner BF Jr, Yu PN. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med 1972; 287:866.</a></li><li><a class="nounderline abstract_t">Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986; 8:436.</a></li><li><a class="nounderline abstract_t">Aslan E, Luo JW, Lesage A, et al. MRI-based R2* mapping in patients with suspected or known iron overload. Abdom Radiol (NY) 2021; 46:2505.</a></li><li><a class="nounderline abstract_t">Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 2001; 107:1545.</a></li><li><a class="nounderline abstract_t">Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 1994; 272:231.</a></li><li><a class="nounderline abstract_t">Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999; 100:1268.</a></li><li><a class="nounderline abstract_t">Tuomainen TP, Kontula K, Nyyssönen K, et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. Circulation 1999; 100:1274.</a></li><li><a class="nounderline abstract_t">Waalen J, Felitti V, Gelbart T, et al. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med 2002; 113:472.</a></li><li><a class="nounderline abstract_t">Salonen JT, Nyyssönen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86:803.</a></li><li><a class="nounderline abstract_t">Pereira AC, Cuoco MA, Mota GF, et al. Hemochromatosis gene variants in patients with cardiomyopathy. Am J Cardiol 2001; 88:388.</a></li><li><a class="nounderline abstract_t">Mänttäri M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994; 15:1599.</a></li><li><a class="nounderline abstract_t">Franco RF, Zago MA, Trip MD, et al. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol 1998; 102:1172.</a></li><li><a class="nounderline abstract_t">Ellervik C, Tybjaerg-Hansen A, Grande P, et al. Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study. Circulation 2005; 112:185.</a></li><li><a class="nounderline abstract_t">Utzschneider KM, Kowdley KV. Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice. Nat Rev Endocrinol 2010; 6:26.</a></li><li><a class="nounderline abstract_t">Nelson RL, Baldus WP, Rubenstein AH, et al. Pancreatic alpha-cell function in diabetic hemochromatotic subjects. J Clin Endocrinol Metab 1979; 49:412.</a></li><li><a class="nounderline abstract_t">Sampson MJ, Williams T, Heyburn PJ, et al. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 2000; 135:170.</a></li><li><a class="nounderline abstract_t">Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984; 101:629.</a></li><li><a class="nounderline abstract_t">Siemons LJ, Mahler CH. Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. J Clin Endocrinol Metab 1987; 65:585.</a></li><li><a class="nounderline abstract_t">Cundy T, Butler J, Bomford A, Williams R. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin Endocrinol (Oxf) 1993; 38:617.</a></li><li><a class="nounderline abstract_t">Hudec M, Grigerova M, Walsh CH. Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion. Thyroid 2008; 18:255.</a></li><li><a class="nounderline abstract_t">Walton C, Kelly WF, Laing I, Bu'lock DE. Endocrine abnormalities in idiopathic haemochromatosis. Q J Med 1983; 52:99.</a></li><li><a class="nounderline abstract_t">Vantyghem MC, Dobbelaere D, Mention K, et al. Endocrine manifestations related to inherited metabolic diseases in adults. Orphanet J Rare Dis 2012; 7:11.</a></li><li><a class="nounderline abstract_t">Fujisawa I, Morikawa M, Nakano Y, Konishi J. Hemochromatosis of the pituitary gland: MR imaging. Radiology 1988; 168:213.</a></li><li><a class="nounderline abstract_t">Sondag MJ, Wattamwar AS, Aleppo G, Nemeth AJ. Case 179: Hereditary hemochromatosis. Radiology 2012; 262:1037.</a></li><li><a class="nounderline abstract_t">Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989; 110:430.</a></li><li><a class="nounderline abstract_t">Edwards CQ, Kelly TM, Ellwein G, Kushner JP. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 1983; 143:1890.</a></li><li><a class="nounderline abstract_t">Brown S, Torrens LA. Ironing out the rough spots--cognitive impairment in haemochromatosis. BMJ Case Rep 2012; 2012.</a></li><li><a class="nounderline abstract_t">Sethi SK, Sharma S, Gharabaghi S, et al. Quantifying Brain Iron in Hereditary Hemochromatosis Using R2* and Susceptibility Mapping. AJNR Am J Neuroradiol 2022; 43:991.</a></li><li><a class="nounderline abstract_t">Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46:1071.</a></li><li><a class="nounderline abstract_t">Smith LH Jr. Overview of hemochromatosis. West J Med 1990; 153:296.</a></li><li><a class="nounderline abstract_t">Carniel E, Mazigh D, Mollaret HH. Expression of iron-regulated proteins in Yersinia species and their relation to virulence. Infect Immun 1987; 55:277.</a></li><li><a class="nounderline abstract_t">Ganz T. Iron and infection. Int J Hematol 2018; 107:7.</a></li><li><a class="nounderline abstract_t">Thwaites PA, Woods ML. Sepsis and siderosis, Yersinia enterocolitica and hereditary haemochromatosis. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Sauter M, Vavricka SR, Locher P, et al. Multilocular Hepatic Abscess Formation and Sepsis due to Yersinia enterocolitica in a Patient with Hereditary Hemochromatosis and Type 2 Diabetes Mellitus. Case Rep Gastroenterol 2017; 11:724.</a></li><li><a class="nounderline abstract_t">Crosbie J, Varma J, Mansfield J. Yersinia enterocolitica infection in a patient with hemachromatosis masquerading as proximal colon cancer with liver metastases: report of a case. Dis Colon Rectum 2005; 48:390.</a></li><li><a class="nounderline abstract_t">Bergmann TK, Vinding K, Hey H. Multiple hepatic abscesses due to Yersinia enterocolitica infection secondary to primary haemochromatosis. Scand J Gastroenterol 2001; 36:891.</a></li><li><a class="nounderline abstract_t">Coppens L, Sztern B, Korman D, Lustman F. Yersinia enterolitica bacteremia with intracranial extension. Scand J Infect Dis 1995; 27:409.</a></li><li><a class="nounderline abstract_t">Gerhard GS, Levin KA, Price Goldstein J, et al. Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation. Arch Pathol Lab Med 2001; 125:1107.</a></li><li><a class="nounderline abstract_t">Barton JC, Acton RT. Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol 2009; 43:890.</a></li><li><a class="nounderline abstract_t">Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932.</a></li><li><a class="nounderline abstract_t">van Asbeck BS, Verbrugh HA, van Oost BA, et al. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J (Clin Res Ed) 1982; 284:542.</a></li><li><a class="nounderline abstract_t">Manso C, Rivas I, Peraire J, et al. Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis. Scand J Infect Dis 1997; 29:308.</a></li><li><a class="nounderline abstract_t">Henrion J, de Neve A, Heller F. [Bacterial septicemia: an unrecognized complication of hemochromatosis. Study of 3 cases and review of the literature]. Acta Clin Belg 1986; 41:10.</a></li><li><a class="nounderline abstract_t">Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313:1256.</a></li><li><a class="nounderline abstract_t">Yang Q, McDonnell SM, Khoury MJ, et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998; 129:946.</a></li><li><a class="nounderline abstract_t">Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985; 75:81.</a></li><li><a class="nounderline abstract_t">Hsing AW, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995; 60:160.</a></li><li><a class="nounderline abstract_t">Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125:1733.</a></li><li><a class="nounderline abstract_t">Atkins JL, Pilling LC, Masoli JAH, et al. Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy. JAMA 2020; 324:2048.</a></li><li><a class="nounderline abstract_t">Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010; 51:1311.</a></li><li><a class="nounderline abstract_t">Lv YF, Chang X, Hua RX, et al. The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants. J Cell Mol Med 2016; 20:1219.</a></li><li><a class="nounderline abstract_t">Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988; 319:1047.</a></li><li><a class="nounderline abstract_t">Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33:647.</a></li><li><a class="nounderline abstract_t">Nelson RL, Davis FG, Persky V, Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer 1995; 76:875.</a></li><li><a class="nounderline abstract_t">Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100:996.</a></li><li><a class="nounderline abstract_t">Gannon PO, Medelci S, Le Page C, et al. Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer 2011; 128:2326.</a></li><li><a class="nounderline abstract_t">Biasiotto G, Roetto A, Daraio F, et al. Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele. Blood Cells Mol Dis 2004; 33:338.</a></li><li><a class="nounderline abstract_t">Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335:1799.</a></li><li><a class="nounderline abstract_t">Fitzsimons EJ, Cullis JO, Thomas DW, et al. Diagnosis and therapy of genetic haemochromatosis (review and 2017 update). Br J Haematol 2018; 181:293.</a></li><li><a class="nounderline abstract_t">Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol 2019; 114:1202.</a></li><li><a class="nounderline abstract_t">Qaseem A, Aronson M, Fitterman N, et al. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 143:517.</a></li><li><a class="nounderline abstract_t">Adams PC, Reboussin DM, Press RD, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007; 120:999.e1.</a></li><li class="breakAll">http://www.choosingwisely.org/clinician-lists/american-college-medical-genetics-genomics-hfe-genetic-testing/.</li><li><a class="nounderline abstract_t">Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138:627.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="214440524d4e4747484244614440524d4e47474842440f4454">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol 2022; 77:479.</a></li><li><a class="nounderline abstract_t">Phatak PD, Barton JC. Phlebotomy-mobilized iron as a surrogate for liver iron content in hemochromatosis patients. Hematology 2003; 8:429.</a></li><li><a class="nounderline abstract_t">Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program 2017; 2017:265.</a></li><li><a class="nounderline abstract_t">Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol 2016; 172:512.</a></li><li><a class="nounderline abstract_t">Cazzola M, Sehn LH. Developing a classification of hematologic neoplasms in the era of precision medicine. Blood 2022; 140:1193.</a></li><li><a class="nounderline abstract_t">Olynyk JK, Ramm GA. Hemochromatosis. N Engl J Med 2022; 387:2159.</a></li><li><a class="nounderline abstract_t">Valenti L, Corradini E, Adams LA, et al. Consensus Statement on the definition and classification of metabolic hyperferritinaemia. Nat Rev Endocrinol 2023; 19:299.</a></li><li><a class="nounderline abstract_t">Girelli D, Bozzini C, Zecchina G, et al. Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. Br J Haematol 2001; 115:334.</a></li><li><a class="nounderline abstract_t">Pietrangelo A. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica 2017; 102:1972.</a></li><li><a class="nounderline abstract_t">Marchi G, Busti F, Lira Zidanes A, et al. Aceruloplasminemia: A Severe Neurodegenerative Disorder Deserving an Early Diagnosis. Front Neurosci 2019; 13:325.</a></li><li><a class="nounderline abstract_t">Marchi G, Nascimbeni F, Motta I, et al. Hyperferritinemia and diagnosis of type 1 Gaucher disease. Am J Hematol 2020; 95:570.</a></li></ol></div><div id="topicVersionRevision">Topic 7167 Version 57.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34601591" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemochromatosis classification: update and recommendations by the BIOIRON Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8696333" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26164493" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genetics, Genetic Testing, and Management of Hemochromatosis: 15 Years Since Hepcidin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346098" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : HFE gene variants affect iron in the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008199" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858186" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hemochromatosis and iron-overload screening in a racially diverse population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922318" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979952" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24729993" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Iron overload is rare in patients homozygous for the H63D mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37121243" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28280078" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pathophysiological consequences and benefits of HFE mutations: 20 years of research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15290237" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The origin and spread of the HFE-C282Y haemochromatosis mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416567" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116301" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inappropriately high iron regulatory protein activity in monocytes of patients with genetic hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27044621" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hepcidin in the diagnosis of iron disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31949017" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Iron metabolism and iron disorders revisited in the hepcidin era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23418762" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hereditary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8110209" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Screening for hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996414" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Detection of iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3367936" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence of hemochromatosis among 11,065 presumably healthy blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9490593" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26633544" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32189932" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemochromatosis in India: First Report of Whole Exome Sequencing With Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21452290" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28771247" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24054178" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hereditary hemochromatosis: missed diagnosis or misdiagnosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23566434" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : [Hereditary hemochromatosis: presenting manifestations and diagnostic delay].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087882" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disease-related conditions in relatives of patients with hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30651232" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012084" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical presentation of hemochromatosis: a changing scene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7887234" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidemiology, clinical spectrum and prognosis of hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657865" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hereditary Hemochromatosis Associations with Frailty, Sarcopenia and Chronic Pain: Evidence from 200,975 Older UK Biobank Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23188073" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High prevalence of fibromyalgia in patients with HFE-related hereditary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871557" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27657935" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422567" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3279862" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association between alcoholism and increased hepatic iron stores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11983453" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788568" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729219" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reduced serum hepcidin levels in patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3680791" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22083147" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Iron overload cardiomyopathy in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035843" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1994. A 25-year-old man with the recent onset of diabetes mellitus and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3799437" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reversible cardiac dysfunction in hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5071966" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reversible cardiomyopathy associated with hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3734266" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33388804" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : MRI-based R2* mapping in patients with suspected or known iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11413162" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Iron overload diminishes atherosclerosis in apoE-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022042" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10491369" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10491370" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427496" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516192" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545759" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hemochromatosis gene variants in patients with cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7698127" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Serum ferritin and ceruloplasmin as coronary risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9753040" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998685" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010968" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/381322" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pancreatic alpha-cell function in diabetic hemochromatotic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695662" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6435491" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hypogonadism in hemochromatosis: reversal with iron depletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3624416" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8334747" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18205549" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6683854" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Endocrine abnormalities in idiopathic haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284844" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Endocrine manifestations related to inherited metabolic diseases in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3380960" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hemochromatosis of the pituitary gland: MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22357904" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Case 179: Hereditary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919850" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6625774" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thyroid disease in hemochromatosis. Increased incidence in homozygous men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22761228" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ironing out the rough spots--cognitive impairment in haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35798390" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Quantifying Brain Iron in Hereditary Hemochromatosis Using R2* and Susceptibility Mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17828789" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2219895" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Overview of hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3793233" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Expression of iron-regulated proteins in Yersinia species and their relation to virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29147843" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Iron and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052950" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sepsis and siderosis, Yersinia enterocolitica and hereditary haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29430224" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Multilocular Hepatic Abscess Formation and Sepsis due to Yersinia enterocolitica in a Patient with Hereditary Hemochromatosis and Type 2 Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812589" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Yersinia enterocolitica infection in a patient with hemachromatosis masquerading as proximal colon cancer with liver metastases: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11495088" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Multiple hepatic abscesses due to Yersinia enterocolitica infection secondary to primary haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8658081" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Yersinia enterolitica bacteremia with intracranial extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11473471" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349902" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hemochromatosis and Vibrio vulnificus wound infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867745" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Management of hemochromatosis. Hemochromatosis Management Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6800535" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255896" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3085416" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : [Bacterial septicemia: an unrecognized complication of hemochromatosis. Study of 3 cases and review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4058506" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867747" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2989605" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829208" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724826" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33231665" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20099304" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : HFE C282Y homozygotes are at increased risk of breast and colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893171" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3173433" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Body iron stores and the risk of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11230745" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625192" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18612130" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20669231" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15528154" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943161" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical and biochemical abnormalities in people heterozygous for hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663319" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Diagnosis and therapy of genetic haemochromatosis (review and 2017 update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31335359" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : ACG Clinical Guideline: Hereditary Hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204164" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976429" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Biological variability of transferrin saturation and unsaturated iron-binding capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976429" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Biological variability of transferrin saturation and unsaturated iron-binding capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12693884" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35662478" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : EASL Clinical Practice Guidelines on haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668040" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Phlebotomy-mobilized iron as a surrogate for liver iron content in hemochromatosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222265" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Iron overload in thalassemia: different organs at different rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26491866" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35834418" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Developing a classification of hematologic neoplasms in the era of precision medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477033" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36805052" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Consensus Statement on the definition and classification of metabolic hyperferritinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11703332" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29101207" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Ferroportin disease: pathogenesis, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31024241" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Aceruloplasminemia: A Severe Neurodegenerative Disorder Deserving an Early Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031266" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Hyperferritinemia and diagnosis of type 1 Gaucher disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
